Skip to main content

Table 4 Prognostic values of clinical variables for predicting progression-free survival in 184 patients with metastatic renal cell carcinoma (all categorical variables) analyzed by using univariate and multivariate Cox regression models

From: Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma

Variable

Univariate

Multivariate

HR (95% CI)

P value

HR (95% CI)

P value

Sex (men vs. women)

1.204 (0.806–1.799)

0.363

  

Age (<65 vs. ≥65 years)

0.999 (0.983–1.016)

0.934

  

Pathologic type (ccRCC vs. nccRCC)

1.408 (0.896–2.221)

0.138

  

History of nephrectomy (yes vs. no)

1.103 (0.691–1.760)

0.681

  

History of cytokine treatment (yes vs. no)

0.963 (0.667–1.391)

0.842

  

Fuhrman grade (1–2 vs. 3–4 and unknown)

1.620 (1.260–2.081)

<0.001*

1.181 (1.147–1.937)

0.196

Number of metastatic sites (1 vs. ≥ 2)

2.010 (1.384-2.918)

<0.001*

1.601 (1.110–2.311)

0.012

MSKCC risk category (favorable and intermediate vs. poor)

1.927 (1.548–2.399)

<0.001*

2.000 (1.060–2.154)

<0.001

NLR (<2.2 vs. ≥2.2)

1.679 (1.201–2.347)

0.002*

1.511 (1.060–2.154)

0.022

Drug category (sorafenib vs. sunitinib)

1.036 (0.725–1.480)

0.847

  

Pre-treatment serum albumin level (≥40.7 g/L vs. <40.7 g/L)

1.432 (1.034–1.984)

0.031*

0.913 (0.631–1.319)

0.627

Post-treatment serum albumin level (≥36.4 g/L vs. <36.4 g/L)

2.392 (1.637–3.494)

<0.001*

2.113 (1.390–3.212)

<0.001

  1. ccRCC, clear cell renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; NLR, neutrophil-to-lymphocyte ratio; MSKCC, Memorial Sloan Kettering Cancer Center; HR, hazard ratio; CI, confidence interval
  2. * Variables with P values <0.05 in univariate analysis were considered for multivariate analysis